
Please try another search
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of Aramchol for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule for the treatment of non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study for HIV-associated lipodystrophy and non-alcoholic fatty liver disease. In addition, it develops products for cardiometabolic indications. The company has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with Virginia Commonwealth University to investigate the effect of adding Aramchol to prevent drug resistance to standard-of-care oncology agents in the treatment of hepatoma, cholangiocarcinoma, and colorectal cancer. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Name | Age | Since | Title |
---|---|---|---|
David Sidransky | 64 | 2014 | Lead Independent Director |
Scott L. Friedman | - | - | Member of Scientific Advisory Board |
Shmuel Nir | 62 | 2007 | Independent Director |
Carol L. Brosgart | 72 | 2017 | Independent Director |
Arun J. Sanyal | - | - | Member of Scientific Advisory Board |
Allen Baharaff | 59 | 2000 | Co-Founder, President, CEO & Chairman |
Amir Poshinski | 63 | 2020 | Independent Director |
Vlad Raziu | - | - | Member of Scientific Advisory Board |
José María Mato de la Paz | - | - | Member of Scientific Advisory Board |
Shomron Ben-Horin | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review